Kite Pharma (KITE) Posts Q1 Loss of 20c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kite Pharma (KITE) Q1 Release Timing, Trial Dosing Has One Analyst Nervous
May 18, 2015 6:44 AM EDTStifel analyst Thomas Shrader weighed in on Kite Pharma (NASDAQ: KITE) following the release of Q1 results after the market closed on Friday. Shrader called the releasing timing "alarming" and suggested maybe it was designed to "avoid 25 consecutive analyst questions amounting to: how is the pivotal trial going?"
Shrader admits the recently initiated pivotal trial for KTE-019 in DLBCL makes them nervous. "Its not that we worry about the results; we have seen enough data that we expect... More
